EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mavorixafor: First Approval

Sheridan M Hoy

Drugs · 2024

DOI: 10.1007/s40265-024-02063-y ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs, 2024. Verfasst von Sheridan M Hoy. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. Hauptthemen laut MEDLINE: Primary Immunodeficiency Diseases, Drug Approval, Receptors, CXCR4. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mavorixafor (XOLREMDI™) is an oral, selective C-X-C chemokine receptor 4 (CXCR4) antagonist developed by X4 Pharmaceuticals that blocks the binding of C-X-C chemokine ligand 12 (also known as stromal derived factor-1) to CXCR4. In April 2024, it became the first therapy to be approved for WHIM syndrome (named by an acronym for its observed characteristics of Warts, Hypogammaglobulinaemia, Infections and Myelokathexis) in the USA, where it is indicated for use in patients aged ≥ 12 years with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes. Clinical development of mavorixafor is ongoing for chronic neutropenic disorders. This article summarizes the milestones in the development of mavorixafor leading to this first approval for use in patients aged ≥ 12 years with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary Immunodeficiency DiseasesDrug ApprovalReceptors, CXCR4HumansNeutrophilsWartsCyclamsImmune System DiseasesChildUnited States

Substanzen

Receptors, CXCR4CyclamsCXCR4 protein, human

Autor:innen und Institutionen

  • Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Zitieren

APA

Hoy, S. M. (2024). Mavorixafor: First Approval. Drugs. https://doi.org/10.1007/s40265-024-02063-y

Vancouver

Hoy SM. Mavorixafor: First Approval. Drugs. 2024. doi:10.1007/s40265-024-02063-y

BibTeX
@article{Hoy2024,
  author = {Hoy, Sheridan M},
  title = {Mavorixafor: First Approval},
  journal = {Drugs},
  year = {2024},
  doi = {10.1007/s40265-024-02063-y}
}
Kostenlos starten →